ClinicalTrials.gg
Active, not recruitingNCT07502066LIDOUpdated Mar 30, 2026

Clinical Efficacy of a telerehabilItation Protocol, for the Improvement of Balance in Degenerative Neurological Diseases

An interventional study of Telerehabilitation Treatment and Conventional Treatment in Multiple Sclerosis and Parkinson Disease, sponsored by IRCCS San Camillo, Venezia, Italy. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by IRCCS San Camillo, Venezia, Italy · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Oct 2021, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 289 studies in Multiple Sclerosis with a site in Italy — 59 open to participants now, 90 under way, 13 of them phase 3. Multiple Sclerosis · Italy.

Planned enrollment
180th of 230
36 · median 115
Started
2021
with 22 others
No phase
105 of 289
33 open now
Primary completion
2026-12
later than 57 of 89 live
Registered
214th of 289
by date

Among the 289 studies in Multiple Sclerosis with a site in Italy, this one is the 180th largest by planned enrollment of the 230 interventional ones that give a count, is one of 23 that started in 2021, is one of 105 with no phase, reaches primary completion later than 57 of the 89 other live ones, and was the 214th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

59 of the 289 studies in Multiple Sclerosis with a site in Italy are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 289 studies in Multiple Sclerosis with a site in Italy, or all of them as a file.
02

Study summary

The goal of this one blind-randomized controlled clinical trial is to evaluate the clinical effectiveness of a telerehabilitation (TR) protocol focusing on balance rehabilitation in patients with neurodegenerative diseases (Parkinson's Disease, Multiple Sclerosis).

The secondary objectives of the study are:

  1. To evaluate the effects of clinical treatment on Health-Related Quality of Life (HRQOL) outcomes.
  2. To collect data on process measures: user needs (patients and caregivers), treatment adherence, usability, satisfaction, technological acceptance.

Participants will perform 20 rehabilitation session (physiotherapy) for balance improvement. Experimental group patients will be trheated through tele-rehabilitation performing exercise with an hospital physiotherapist.

Researchers will compare telerehabilitation group to usual care group to see if there is a significant improvement in motor function, particularly in balance and mobility tests, as well as an improvement in quality of life.

Read the detailed description

Single-blind randomised controlled clinical trial. A sample of 36 consecutive patients (18 per group) suffering from Multiple Sclerosis (N=18, 9 per group) and Parkinson's Disease (N=18, 9 per group), admitted to the San Camillo IRCCS Hospital in Venice in ordinary inpatient or outpatient care, who still need home rehabilitation, will be enrolled. patients will be randomised to receive either TR or usual care, based on an allocation generated by the website: "Sealed Envelope.com". After discharge and before treatment (T1), a researcher will conduct blinded clinical assessments, repeated after 20 rehabilitation sessions (T2), and 2 months after the end of treatment (T3). The rehabilitation modality provided by the IRCCS in telerehabilitation is based on virtual reality modalities. In particular, the experimental treatment under study involves the use of the VRRS-TR system (Khymeia Group s.r.l, Noventa Padovana), which consists of

  • n.1 Tablet complete with keyboard, power supply, telerehabilitation application (Virtual Reality Rehabilitation System- VRRS);
  • no.1 multi-USB device with cable for USB-mini port
  • n.1 video camera;
  • no.1 wide-angle lens and its attachment;
  • no.1 K-wand;
  • no.2 KHIMU wireless inertial sensors with power supply
  • 1 USB dongle for communication with KHIMU sensors
  • n.7 Velcro strips These technologies will be delivered to the patient and will be used at home, through a two-way on-line connection by means of Synchronous Telerehabilitation, with an IRCCS physiotherapist, who will deliver the treatments through a dedicated workstation (Telecokpit), with which it will be possible to manage the patient's tablet through the "Teamviewer" app, interacting with the latter and monitoring the execution of the exercises through the videoconference implemented in the system.

The virtual environment makes it possible to administer a high dose of repetitions of the movement of interest; for each exercise, the quality of execution is monitored in real time, i.e. through the return of feedback to the subject through visual, acoustic and vocal indications. Finally, various parameters, such as the distance of the targets to be reached, the sensitivity, the number of repetitions and the dwell time on the different targets, allow the difficulty of the exercise to be increased or decreased. In order to perform the rehabilitation protocol in telerehabilitation, inertial sensors (KhyMU) are used, which are applied to the part of the body that will become the effector of the movement. The sensors are applied using special elastic bands on the front part of the trunk and the front part of the thighs/legs/arms. Depending on the movement to be trained, the therapist decides whether to use one sensor or both.The exercises proposed to the control group will be performed by the latter at home, in self-treatment. Type, intensity, duration and objectives of these exercises are structured to be as similar and homogeneous as possible to those performed by means of the VRRS system in Telerehabilitation. In order to carry out the therapies, the patient will be given a booklet with a precise description of the exercises to be performed accompanied by explanatory pictures. This file is created through the website: www.physiotherapyexercises.com. On a weekly basis, a physiotherapist will contact the patient by telephone to inquire about the progress of the therapies, giving indications on how to modify the modalities, number of repetitions, duration and difficulty of the exercises, maintaining the logic of incremental training adopted in the TR group protocol. The patient will also be provided with a monitoring diary of the activities performed, corresponding to the automatic reporting system implemented in the VRRS system, used instead for the TR group.

Follow-up (T3) At the end of the treatment protocol, two months after the final evaluation (T2), a Follow-Up will be carried out by means of a brief telephone survey to monitor the state of health, autonomy in ADLs, number of falls and perception of safety with respect to one's own balance of the patients enrolled in this project.

03

Conditions studied

  • Multiple Sclerosis
  • Parkinson Disease

Keywords

  • Telerehabilitation
  • Balance Treatment
  • remote rehabilitation
  • remote monitoring
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Possession of an ADSL internet connection with a flat rate or, in the case of a pay-as-you-go tariff, with an availability of at least 20 Gigabytes/month.

PARKINSON'S DISEASE:

  • Patients with Parkinson's disease, according to the criteria of the UK Parkinson's Disease Society Brain Bank, in stabilised pharmacological treatment with L-Dopa or dopamine agonists and with a Hoehn \& Yahr scale score between 1.5 and 2.5;
  • Patients presenting a score ≤ 2 in the 'freezing when walking' subitem of section II of the UPDRS;
  • Patients presenting a score ≤ 2 in both duration and disability in the "dyskinesias" sub-item of section IV of the UPDRS.

MULTIPLE SCLEROSIS

  • Subjects with Multiple Sclerosis (MS) in the relapsing remitting (RRMS) or secondary progressive (SPMS) forms, according to the criteria of MC Donald 2010 [14], under stable drug treatment and with Expanded Disability Status Scale (EDSS) score ≤ 6.5;
  • At the time of inclusion, at least 3 months have elapsed since the last relapse.

Exclusion criteria

Exclusion Criteria:

  • All patients will be excluded from the study who, in association with the diagnosis of the diseases listed above, have the following comorbidities diagnosed and documented in the medical records
  • Unstabilised fractures;
  • Diagnosis of major depression;
  • Severe deficits in visual acuity and hearing perception;
  • Dementia;
  • Epilepsy not controlled pharmacologically;
  • Ideomotor apraxia;
  • Neglect;
  • Severe impairment of verbal comprehension
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Telerehabilitation Group- Multiple Sclerosis (TR-MS)

    After discharge and before treatment (T1), a researcher will conduct blinded clinical assessments, repeated after 20 rehabilitation sessions (T2), and 2 months after the end of treatment (T3). The rehabilitation modality provided by the IRCCS in telerehabilitation is based on virtual reality modalities. In particular, the experimental treatment under study involves the use of the VRRS-TR system (Khymeia Group s.r.l, Noventa Padovana). Every session will last 1h and will be done 5 times/week for 4 week.

    Other: Telerehabilitation Treatment

  • Active comparator
    Control Group- Multiple Sclerosis (CG-MS)

    After discharge and before treatment (T1), a researcher will conduct blinded clinical assessments, repeated after 20 rehabilitation sessions (T2), and 2 months after the end of treatment (T3).Every session will last 1h and will be done 5 times/week for 4 week.The exercises proposed to the control group will be performed by the patient at home, in self-treatment.In order to carry out the therapies, the patient will be given a booklet with a precise description of the exercises to be performed accompanied by explanatory pictures. This file is created through the website: www.physiotherapyexercises.com. On a weekly basis, a physiotherapist will contact the patient by telephone to inquire about the progress of the therapies. The patient will also be provided with a monitoring diary of the activities performed, corresponding to the automatic reporting system implemented in the VRRS system, used instead for the TR group.

    Other: Conventional Treatment

  • Experimental
    Telerehabilitation Group- Parkinson's Disease (TR-PD)

    After discharge and before treatment (T1), a researcher will conduct blinded clinical assessments, repeated after 20 rehabilitation sessions (T2), and 2 months after the end of treatment (T3). Every session will last 1h and will be done 5 times/week for 4 week.The rehabilitation modality provided by the IRCCS in telerehabilitation is based on virtual reality modalities. In particular, the experimental treatment under study involves the use of the VRRS-TR system (Khymeia Group s.r.l, Noventa Padovana).

    Other: Telerehabilitation Treatment

  • Active comparator
    Control Group- Parkinson's Disease ( CG-PD)

    After discharge and before treatment (T1), a researcher will conduct blinded clinical assessments, repeated after 20 rehabilitation sessions (T2), and 2 months after the end of treatment (T3).Every session will last 1h and will be done 5 times/week for 4 week.The exercises proposed to the control group will be performed by the patient at home, in self-treatment.In order to carry out the therapies, the patient will be given a booklet with a precise description of the exercises to be performed accompanied by explanatory pictures. This file is created through the website: www.physiotherapyexercises.com. On a weekly basis, a physiotherapist will contact the patient by telephone to inquire about the progress of the therapies. The patient will also be provided with a monitoring diary of the activities performed, corresponding to the automatic reporting system implemented in the VRRS system, used instead for the TR group.

    Other: Conventional Treatment

Interventions

  • OtherTelerehabilitation Treatment

    The treatment will last 4 weeks; each session will be1 hour, to be performed five times a week. Patients in the Telerehabilitation group will perform the same balance rehabilitation protocol as the controls, through the telerehabilitation system implemented by the IRCCS, which allows them to perform rehabilitation treatments at home, monitored by a hospital physiotherapist. Both groups will carry out a clinical evaluation before and after the treatments and will be contacted again briefly two months after the end of the treatment to ascertain the maintenance of the results obtained.

    Also known as: remote rehabilitation

  • OtherConventional Treatment

    The conventional treatment group will perform a programme of exercises, specific for balance, contained in a booklet, in which there is a description of the activities, accompanied by explanatory pictures. On a weekly basis, a physiotherapist will contact the individuals in this group by telephone to inquire about the progress of the therapy, and provide information on how to possibly modify the mode, number of repetitions, duration and difficulty of the exercises. In addition, the patient will be provided with a diary to monitor the activities performed. The treatment will last four weeks; each session will be one hour, to be performed five times a week.

    Also known as: usual care treatment

06

What researchers measure

Primary outcomes

  1. Berg Balance Scale

    The Berg Balance Scale (BBS) objectively assesses a patient's ability to safely maintain balance during 14 predetermined tasks. Each item is scored on a 5-point ordinal scale (0-4), with 0 indicating the lowest level of function and 4 the highest. The assessment takes approximately 20 minutes and excludes gait evaluation. Possible scores range from 0 to 56, with higher scores indicating better balance function.

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

Secondary outcomes

  1. Mini-Balance Evaluation System Test (Mini-BESTest)

    The Mini-BESTest evaluates dynamic balance, functional mobility, and gait through 14 items across four sections: anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. Possible scores range from 0 to 28, with higher scores indicating better postural control and balance function.

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

  2. Functional Ambulation Classification (FAC)

    FAC is a 6-point functional walking test that evaluates ambulation ability by determining the level of human support required when walking, regardless of assistive devices used. Scores range from 0 (non-functional ambulator) to 5 (independent ambulator on any surface), with higher scores indicating better independence in ambulation.

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

  3. 5X Sit-to-Stand Test (5XSST)

    5x Sit-To-Stand Test assesses functional lower extremity strength, transitional movements, balance, and fall risk, measuring the time taken to rise from a chair 5 times. Scores are time in seconds (typically 5-30 seconds in adults), with lower time ndicating better lower limb strength and balance.

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

  4. Activities specific-Balance Confidence (ABC) -Scale

    ABC scale is s a 16-item questionnaire measuring confidence in performing ambulatory activities without losing balance or feeling unsteady. Scores range from 0% (no confidence) to 100% (complete confidence), with higher scores indicating greater balance confidence.

    Time frame: Change from Baseline (T1) to Follow-up (T3), approximately 12 weeks after baseline.

  5. Barthel Index (BI)

    BI is an ordinal scale measuring performance in 10 activities of daily living (ADL) and mobility, based on time and assistance required. Scores range from 0 (total dependence) to 100 (complete independence), with higher scores indicating better functional independence.

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

  6. Six Minutes Walking Test (6MWT)

    6MWT is a sub-maximal exercise test assessing aerobic capacity and endurance by measuring distance covered in 6 minutes. Scores are distance in meters (typically 300-700m in adults), with greater distances indicating better endurance.

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline

  7. Ten metres walking test (10MWT)

    10MWT assesses walking speed in meters per second over a short distance to evaluate functional mobility, gait, and vestibular function. Scores are time in seconds or speed in m/s (typically 0.8-1.5 m/s), with faster speeds (lower times) indicating better gait performance.

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

  8. Short-Form-36 health outcome (SF-36)

    SF-36 is a self-reported measure of health-related quality of life across eight domains, yielding Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Domain scores range 0-100; PCS and MCS standardized to mean 50 (SD 10), with higher scores indicating better health status.

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

  9. Falls questionnaire (last year-last 2 months)

    Self-produced questionnaire monitoring the number of falls occurring during the previous year and the two months prior to administration, including circumstances of falls. Scores are count of falls (0 or more), with fewer falls indicating better outcome.

    Time frame: Change from Baseline (T1) to Follow-up (T3), approximately 12 weeks after baseline.

  10. EuroQol-5 Dimensions, 3 Levels (EQ-5D-3L)

    The EQ-5D is a self-completion questionnaire assessing health-related quality of life across five dimensions plus a visual analog scale, yielding an index score. Index scores range from -0.594 (worse than dead) to 1 (perfect health), with higher scores indicating better health status.

    Time frame: Change from Baseline (T1) to Follow-up (T3), approximately 12 weeks after baseline.

  11. Instrumental Activities of Daily Living (IADL)

    IALS assesses ability to perform complex community-living tasks independently (Lawton scale). Scores range from 0 (low functioning, dependent) to 8 (high functioning, independent), with higher scores indicating better independence.

    Time frame: Change from Baseline (T1) to Follow-up (T3), approximately 12 weeks after baseline.

  12. Client Satisfaction Measure Questionnaire (SMQ)

    Custom questionnaire measuring patient satisfaction with the received therapy. Scores range to be specified (e.g., 0-100 if Likert-based), with higher scores indicating greater satisfaction.

    Time frame: At Post-intervention (T2), approximately 6 weeks after baseline.

  13. System Usability Scale (SUS)

    The System Usability Scale (SUS) is a 10-item questionnaire providing a reliable measure of system usability. Scores range from 0 to 100, with higher scores indicating better perceived usability (≥68 acceptable).

    Time frame: At Post-intervention (T2), approximately 6 weeks after baseline.

  14. Technology acceptance questionnaire (TAM)

    Custom questionnaire based on the Technology Acceptance Model (TAM), measuring patient acceptance of the technology used through constructs like perceived usefulness, perceived ease of use, and behavioral intention. Individual items scored on a 7-point Likert scale (1=strongly disagree to 7=strongly agree); composite/mean scores range from 1 to 7, with higher scores indicating greater technology acceptance.

    Time frame: At Post-intervention (T2), approximately 6 weeks after baseline.

07

Study locations

1 site
08

References and documents

Publications

  • Chirra M, Marsili L, Wattley L, Sokol LL, Keeling E, Maule S, Sobrero G, Artusi CA, Romagnolo A, Zibetti M, Lopiano L, Espay AJ, Obeidat AZ, Merola A. Telemedicine in Neurological Disorders: Opportunities and Challenges. Telemed J E Health. 2019 Jul;25(7):541-550. doi: 10.1089/tmj.2018.0101. Epub 2018 Aug 23. PubMed 30136898 ↗
  • Yang WC, Wang HK, Wu RM, Lo CS, Lin KH. Home-based virtual reality balance training and conventional balance training in Parkinson's disease: A randomized controlled trial. J Formos Med Assoc. 2016 Sep;115(9):734-43. doi: 10.1016/j.jfma.2015.07.012. Epub 2015 Aug 13. PubMed 26279172 ↗
  • Khan F, Amatya B, Kesselring J, Galea M. Telerehabilitation for persons with multiple sclerosis. Cochrane Database Syst Rev. 2015 Apr 9;2015(4):CD010508. doi: 10.1002/14651858.CD010508.pub2. PubMed 25854331 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Dec 2026, 62 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 62 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2023
First posted
Mar 30, 2026
StartActual
Oct 14, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07502066
Lead sponsor
IRCCS San Camillo, Venezia, Italy
Responsible party
Sara Federico (Dr, IRCCS San Camillo, Venezia, Italy) — Principal investigator
First posted
Mar 30, 2026
Start date
Oct 14, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 30, 2026

Study contacts

Sara Federico, PhD
principal investigator · IRCCS San Camillo Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion